
|Videos|October 14, 2017
Dr. Zandberg on the Role of Durvalumab in Head and Neck Cancer
Author(s)Dan Zandberg, MD
Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.
Advertisement
The phase II HAWK trial investigated durvalumab in patients with metastatic head and neck cancer who were PD-L1 high, states Zandberg. Promising outcomes were seen with an overall response rate (ORR) of 16% and durable response of 55%. The median overall survival was 7 months with a 1-year survival of 33%.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































